Cardiologists Conference

September 11, 2017 — Researchers have led a retrospective single-center study examining simple hemodynamic parameters obtained at the time of cardiac catheterization to predict in-hospital mortality following ST-elevation myocardial infarction (STEMI). Current 30-day mortality rates for primary percutaneous coronary intervention (PCI) patients with STEMI range from 2.5 to 10 percent, and 10.5 to 24 percent of those patients require mechanical hemodynamic support.

A cardiovascular service line manager reader of DAIC recently e-mailed me and asked if I had a list of the top technologies that will likely change cardiology in the next few years. He wanted this information for a capital improvement planning for the next decade. I did not have this compilation handy, so I wrote the following list of 17 technology trends I feel will change how cardiology is practiced over the next 10 years, based on my industry observations. These items are not listed in any particular order of importance:

September 8, 2017 — ClearFlow Inc. announced recently that positive clinical trial results were presented at the International Coronary Congress (ICC) 2017 annual meeting, Aug. 18-20 in New York City. The findings were presented by the study principal investigator Yvon Baribeau, M.D., FACS, of Catholic Medical Center in Manchester, N.H., in a presentation titled “Active Clearance of Chest Drains Reduces Retained Blood and ICU Resources after Off-Pump Coronary Artery Bypass Surgery.”

Abbott will end sales of the Absorb bioresorbable stent scaffold, pulling it off the market September 14, 2017.

September 8, 2017 — Abbott Vascular has announced it will end commercial sales of its Absorb bioresorbable vascular scaffold as of Sept. 14, 2017. The company said low sales of the bioabsorbable stent led to the decision to stop offering the product.  

September 7, 2017 — Sapheneia and Scannerside received U.S. Food and Drug Administration (FDA) 510(k) clearance to market their XR-29 DoseCheck solution.

The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory Committee (MIDAC) on Sept. 8 to discuss regulatory approaches for use of gadolinium-based contrast agents (GBCAs).

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to late-breaking research presented today in a Hot Line Late-breaking Clinical Trial session at he European Society of Cardiology (ESC) Congress. The results of the The Left Atrial Appendage Closure by Surgery (LAACS) study suggest that LAA closure should be routinely added to open heart surgery.
Giving oxygen to patients suffering a heart attack is not beneficial, according to the DETO2X-AMI study.

September 7, 2017 — Oxygen therapy does not improve survival in patients with heart attack symptoms, according to late-breaking research from the DETO2X-AMI Study presented in a Hot Line session at the European Society of Cardiology (ESC) Congress and published in the New England Journal of Medicine (NEJM).
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now